Vinod Kumar Viswanathan

Dr. Vinod Kumar Viswanathan

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2023 in Indian Journal of Tuberculosis
Verified
Journal Article
Closed access
VVVinod Kumar Viswanathan
Vinod Kumar Viswanathan

28 September 2024 in Pulmonary Therapy
Verified
Journal Article
Open access
PDF file
VVVinod Kumar Viswanathan
Vinod Kumar Viswanathan
AGAloke G. Ghoshal
Aloke G. Ghoshal
AMAnant Mohan
Anant Mohan
KPKetaki Patil
Ketaki Patil
CBChaitanya Bhargave
Chaitanya Bhargave
SMSuyog C Mehta
Suyog C Mehta
A severe and progressive interstitial lung disease (ILD) known as idiopathic pulmonary fibrosis (IPF) has an unknown etiology with poorly defined mechanisms of development. Among the currently prescribed pharmacological interventions for IPF, nintedanib demonstrates the ability to decelerate the deterioration of lung function and yield positive clinical outcomes. Multiple randomized placebo-controlled trials have confirmed the efficacy and acceptable safety profile of nintedanib. Real-world evidence studies also support the use of nintedanib in IPF, being an efficient and well-tolerated treatment option. It has the potential to stabilize the disease progression in patients with ILD. Patients with IPF frequently have comorbidities like diabetes and hypertension, which can exacerbate the course of disease, reduce quality of life, and decrease treatment adherence. For well-informed decision-making, it is important for healthcare professionals to recognize the position of nintedanib therapy in IPF with comorbidities. The gastrointestinal adverse effects, notably diarrhea, dominate the nintedanib safety profile. These can be effectively controlled by closely monitoring side effects, administering anti-diarrheal and anti-emetic drugs, reducing the nintedanib dose, and discontinuing it in case of severe symptoms with an option to reintroduce the treatment after side effects subside. Symptomatic interventions and monitoring of liver enzymes may reduce the occurrence of permanent treatment discontinuations.

2 April 2025 in Cureus
Verified
Journal Article
Open access
PDF file
VVVinod Kumar Viswanathan
Vinod Kumar Viswanathan
Secondary spontaneous pneumothorax is typically caused by tuberculosis or emphysema. Other causes include interstitial lung disease, pneumoconiosis, organizing pneumonias, and rare conditions like Langerhans cell histiocytosis and lymphangiomyomatosis. Rheumatoid arthritis is an uncommon cause of recurrent secondary spontaneous pneumothorax due to the rupture of subpleural necrobiotic nodules. Drugs like methotrexate and leflunomide are known to accelerate the development and progression of these necrobiotic nodules. Although the exact mechanism is unknown, it is believed to result from decreased monocyte activity and increased rheumatoid factor, with macrophages acting as a nidus that interacts with rheumatoid factor to form a nodule, ultimately leading to pneumothorax when it communicates with the pleural space. This report presents a rare case of recurrent spontaneous pneumothorax resulting from the rupture of subpleural necrobiotic nodules in a patient with rheumatoid arthritis-associated lung disease.

30 April 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
JRJeevarahini Regupathy
Jeevarahini Regupathy
PRPRIYA RAJENDRAN
PRIYA RAJENDRAN
VVVinod Kumar Viswanathan
Vinod Kumar Viswanathan
SSSivakumar Shanmugam
Sivakumar Shanmugam
Tuberculosis (TB) poses serious challenges to healthcare personnel as it continues to be highly prevalent in a developing country like India. Several prominent strategies have been adopted to control this contagious infection, but the incidence rate remains high. Many studies have linked fungal infections to TB, apparently elevating concerns in the TB elimination program. Hence, it is essential to understand the mechanisms underlying TB co-infection and pulmonary mycoses to combat the problems caused by these diseases successfully. In addition, differential diagnosis of TB and fungal infections is equally essential to initiate appropriate treatment. This review attempts to describe misdiagnosis of TB and fungal disease and their relative coexistence in the context of the Indian perspective.

1 May 2021 in Journal of Association of Pulmonologist of Tamil Nadu
Verified
Journal Article
Open access
RSR. Sridhar
R. Sridhar
VVVinod Kumar Viswanathan
Vinod Kumar Viswanathan
RSReetu Singh
Reetu Singh
RKRafeeqa Keyzare
Rafeeqa Keyzare
Introduction: Analysis of tuberculosis (TB) mortality serves to understand the impact of health delivery services and steps needed to eliminate the global burden of TB. With the advent of the COVID pandemic in 2020, there were challenges in delivery of TB services, and this study was undertaken to understand the impact of pandemic on TB mortality. Methodology: Retrospective analysis of death records of patients died due to TB in the year 2020 was done. Results: The data of 250 patients who died due to TB in GHTM in 2020 were analyzed. Most were males in the productive age group of 20 to 60 years. Sputum positivity, male gender, drug resistance, and presence of comorbidities such as DM and HIV contributed to most of the mortality. A drop in presumptive TB cases and notification of TB cases compared to the previous years was noted. Discussion: The demographic profile of patients and risk factors for TB mortality in this study was consistent with known risk factors such as male, sputum positive status, drug resistance, and comorbidities. Drop in notification of TB cases due to the pandemic was noted, and necessary steps for tracing and diagnosing these cases will help reduce mortality due to impact of the pandemic. Analysis of mortality data also reflects on the need for early diagnosis and the use of appropriate treatment protocols and need for new drugs to eliminate and reduce TB mortality. Conclusion: This study emphasises on the need for ensuring continued diagnosis and uninterrupted treatment of TB even in pandemic situations to make the goal of TB elimination a reality.

16 January 2025 in Indian Journal of Tuberculosis
Verified
Journal Article
Closed access
VVVinod Kumar Viswanathan
Vinod Kumar Viswanathan
VAV.K. Arora
V.K. Arora